25 April 2025 false No description of principal activity Taxfiler 2024.6 16409284 business:PrivateLimitedCompanyLtd 2025-04-25 2026-04-30 16409284 2025-04-24 16409284 2025-04-25 2026-04-30 16409284 business:AuditExempt-NoAccountantsReport 2025-04-25 2026-04-30 16409284 business:AbridgedAccounts 2025-04-25 2026-04-30 16409284 2026-04-30 16409284 business:Director1 2025-04-25 2026-04-30 16409284 business:RegisteredOffice 2025-04-25 2026-04-30 16409284 core:WithinOneYear 2026-04-30 16409284 core:AfterOneYear 2026-04-30 16409284 core:ShareCapital core:PreviouslyStatedAmount 2026-04-30 16409284 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2026-04-30 16409284 core:PreviouslyStatedAmount 2026-04-30 16409284 business:SmallEntities 2025-04-25 2026-04-30 16409284 countries:EnglandWales 2025-04-25 2026-04-30 iso4217:GBP xbrli:pure
Company Registration No. 16409284 (England and Wales)
SPRING HILL PHARMA LIMITED Unaudited accounts for the period from 25 April 2025 to 30 April 2026
SPRING HILL PHARMA LIMITED Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
SPRING HILL PHARMA LIMITED Company Information for the period from 25 April 2025 to 30 April 2026
Director
Sardar Hassan Shabir
Company Number
16409284 (England and Wales)
Registered Office
Saydon Ltd 408 Coventry Road Small Heath Birmingham West Midlands B10 0UF England
- 3 -
SPRING HILL PHARMA LIMITED Statement of financial position as at 30 April 2026
2026
Notes
£
Fixed assets
Intangible assets
4
316,362
Tangible assets
5
1,705
318,067
Current assets
Inventories
30,986
Debtors
138,583
Cash at bank and in hand
3,661
173,230
Creditors: amounts falling due within one year
(201,933)
Net current liabilities
(28,703)
Total assets less current liabilities
289,364
Creditors: amounts falling due after more than one year
(259,000)
Net assets
30,364
Capital and reserves
Called up share capital
1
Profit and loss account
30,363
Shareholders' funds
30,364
For the period ending 30 April 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
The members have agreed to the preparation of abridged accounts for the period in accordance with Section 444(2A).
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 3 July 2026 and were signed on its behalf by
Sardar Hassan Shabir Director Company Registration No. 16409284
- 4 -
SPRING HILL PHARMA LIMITED Notes to the Accounts for the period from 25 April 2025 to 30 April 2026
1
Statutory information
SPRING HILL PHARMA LIMITED is a private company, limited by shares, registered in England and Wales, registration number 16409284. The registered office is Saydon Ltd, 408 Coventry Road, Small Heath, Birmingham, West Midlands, B10 0UF, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Intangible fixed assets
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
4
Intangible fixed assets
Total
£
Cost
At 25 April 2025
-
Additions
351,513
At 30 April 2026
351,513
Amortisation
At 25 April 2025
-
Charge for the period
35,151
At 30 April 2026
35,151
Net book value
At 30 April 2026
316,362
- 5 -
SPRING HILL PHARMA LIMITED Notes to the Accounts for the period from 25 April 2025 to 30 April 2026
5
Tangible fixed assets
Total
£
Cost or valuation
At 25 April 2025
-
Additions
2,080
At 30 April 2026
2,080
Depreciation
Charge for the period
375
At 30 April 2026
375
Net book value
At 30 April 2026
1,705
6
Average number of employees
During the period the average number of employees was 1.
- 6 -